Nuvation Bio is a clinical-stage biopharmaceutical company developing therapeutic candidates focused on treating patients with cancers. Co. is developing six wholly owned compounds that have resulted from its drug discovery and development programs, which include: NUV-422, a selective small molecule inhibitor of cyclin-dependent kinase; NUV-868, a BD2-selective oral small molecule bromodomain and extra-terminal inhibitor; NUV-569, an oral small molecule selective inhibitor of Wee1 kinase, a regulator of DNA damage repair; and a drug-drug conjugate platform, which is a therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates. The NUVB average annual return since 2020 is shown above.
The Average Annual Return on the NUVB average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether NUVB average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the NUVB average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|